Eton Pharmaceuticals, Inc. (ETON) Operating Margin
- Operating margin · 12 months: Value 15.44%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 15.44% | Operating income / revenue. Period ending 2026-06-30. $16.31M ÷ $105.59M × 100 ≈ 15.44% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 16.31M USD | Operating Income (Loss) |
| Revenue | 105.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 44.49M USD | Cost of Goods and Services Sold |
| Research and development | 5.76M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16.31M | $105.59M | $44.49M | $5.76M | (m) | 15.44% |
| 2026-03-31 | $2.04M | $86.93M | $39.32M | $8.48M | (m) | 2.35% |
| 2025-12-31 | $-844.00K | $79.95M | $37.21M | $7.76M | (m) | -1.06% |
| 2025-09-30 | $-2.68M | $70.32M | $34.20M | $5.11M | (m) | -3.81% |
| 2025-06-30 | $-807.00K | $58.18M | $23.62M | $4.51M | (m) | -1.39% |
| 2025-03-31 | $-2.27M | $48.33M | $20.06M | $3.77M | (m) | -4.69% |
| 2024-12-31 | $-2.60M | $39.01M | $15.60M | $3.25M | (m) | -6.66% |
| 2024-09-30 | $-5.22M | $34.68M | $14.11M | $5.17M | (m) | -15.05% |
| 2024-06-30 | $-6.28M | $31.38M | $12.71M | $5.28M | (m) | -20.00% |
| 2024-03-31 | $542.00K | $34.30M | $11.58M | $3.44M | (m) | 1.58% |
| 2023-12-31 | $-1.19M | $31.64M | $10.58M | $3.32M | (m) | -3.77% |
| 2023-09-30 | $1.86M | $32.83M | $9.04M | $3.22M | (m) | 5.68% |
| 2023-06-30 | $-484.00K | $29.02M | $7.61M | $3.35M | (m) | -1.67% |
| 2023-03-31 | $-5.71M | $24.38M | $8.04M | $2.91M | (m) | -23.41% |
| 2022-12-31 | $-8.26M | $21.25M | $6.93M | $4.00M | (m) | -38.87% |
| 2022-09-30 | $-8.01M | $18.85M | (m) | $3.73M | (m) | -42.49% |
| 2022-06-30 | $-10.96M | $16.40M | (m) | $5.67M | (m) | -66.82% |
| 2022-03-31 | $-11.95M | $12.11M | (m) | $6.97M | (m) | -98.63% |
| 2021-12-31 | $-1.50M | $21.83M | (m) | $6.24M | (m) | -6.85% |
| 2021-09-30 | $-10.23M | $15.82M | (m) | $8.96M | (m) | -64.66% |
| 2021-06-30 | $-10.65M | $14.88M | $1.88M | $9.10M | (m) | -71.58% |
| 2021-03-31 | $-12.87M | $11.84M | $1.77M | $8.72M | (m) | -108.70% |
| 2020-12-31 | $-27.11M | $39.00K | $286.00K | $14.10M | (m) | -69515.38% |
| 2020-09-30 | $-22.35M | $417.00K | (m) | $10.94M | (m) | -5358.99% |
| 2020-06-30 | $-21.12M | $578.00K | (m) | $11.53M | (m) | -3653.46% |
| 2020-03-31 | $-19.93M | $558.00K | (m) | $11.36M | (m) | -3571.33% |
| 2019-12-31 | $-18.60M | $959.00K | $453.00K | $11.55M | (m) | -1939.62% |
| 2019-09-30 | $-18.23M | (m) | (m) | $12.42M | (m) | (m) |
| 2019-06-30 | $-15.56M | (m) | (m) | $10.55M | (m) | (m) |
| 2019-03-31 | $-14.91M | (m) | (m) | $10.82M | (m) | (m) |
| 2018-12-31 | $-10.32M | (m) | (m) | $5.63M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |